What Can We Learn From The Investigation Of Misconduct?

[Editor's note: Discussions of research misconduct are becoming more and more prevalent, in the halls of academic and research institutions as well as on the front pages of newspapers. But few in the scientific community have experienced the issue as personally as the six authors of the now infamous Cell paper, among them MIT's David Baltimore and Tufts' Thereza ImanishiKari. Since May 1986, when Margot O'Toole, a postdoc working in Imanishi-Kari's lab at MIT, first raised doubts about some of t

| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

In the most recent hearing, held last month, Rep. John Dingell (DMich.), chairman of the Subcommittee on Oversight and Investigations of the House Energy and Commerce Committee, asked several people to describe how their institutions handled—or mishandled—the allegations brought by O'Toole.

What follows are excerpts from the testimonies of key figures in the dispute. The comments are not intended to prove or disprove specific allegations, nor are they meant to provide any kind of overview of this one case. Rather, they are reprinted here to provide a glimpse into how scientists at the center of such a dispute do their jobs, how they see themselves, and how they are viewed by others; as well as to illuminate some personal elements of a bitter and protracted debate.]

So what is the case against us? That there are legitimate disagreements over the results of our work? This I recognize and encourage. That ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies